米托胍腙用于晚期头颈部鳞状细胞癌患者的II期试验。
Phase II trial of mitoguazone in patients with advanced squamous cell carcinoma of the head and neck.
作者信息
Perry D J, Crain S M, Weltz M D, Wilson J P, Davis R K, Woolley P V, Forastiere A A, Taylor H G, Weiss R B
出版信息
Cancer Treat Rep. 1983 Jan;67(1):91-2.
We used mitoguazone (500 mg/m2 iv weekly, with 50-mg/m2 escalations weekly as tolerated) to treat 22 patients with squamous cell carcinoma of the head and neck which recurred after initial therapy. Nine of 22 (11%) patients responded: two had complete responses and seven had partial responses. Gastrointestinal toxicity and anemia were commonly seen. We conclude that mitoguazone is active in squamous cell carcinoma of the head and neck and should be incorporated into phase III trials.
我们使用丙脒腙（静脉注射，500mg/m²，每周一次，根据耐受情况每周递增50mg/m²）治疗22例头颈部鳞状细胞癌患者，这些患者在初始治疗后复发。22例患者中有9例（11%）有反应：2例完全缓解，7例部分缓解。常见胃肠道毒性和贫血。我们得出结论，丙脒腙对头颈部鳞状细胞癌有活性，应纳入III期试验。
Zotero 插件